Diffuse Intrinsic Pontine Glioma Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight

(Albany, USA) DelveInsight's, "Diffuse Intrinsic Pontine Glioma Pipeline Insight" report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the Diffuse Intrinsic Pontine Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Intrinsic Pontine Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report
• DelveInsight's Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ Diffuse Intrinsic Pontine Glioma companies working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
• The leading Diffuse Intrinsic Pontine Glioma Companies working in the market include Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
• Promising Diffuse Intrinsic Pontine Glioma Pipeline Therapies in the various stages of development includes BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.
• December 2023: Luca Szalontay announced a study of Phase 1 clinical trials for Infusate with MTX110 and gadolinium. The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.
• December 2023: Sabine Mueller, MD, PhD announced a study of Phase 1 & 2 clinical trials for Nivolumab and K27M peptide. This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the H3.3.K27M epitope given in combination with poly-ICLC and the H3.3.K27M epitope given in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children with newly diagnosed DIPG or other midline gliomas that are positive for H3.3K27M.
• December 2023: Y-mAbs Therapeutics announced a study of Phase 1 clinical trials for Radioactive iodine-labeled monoclonal antibody omburtamab. In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at different dose levels. They will look to see what effects (both good and bad) it has on the patient. The dose of 124I-omburtamab will increase for each new group of patients. The procedure has already been safely performed with lower doses and infusion volumes in a number of patients here at MSKCC. The amount they get will depend on when they enter the study.

Request a sample and discover the recent advances in Diffuse Intrinsic Pontine Glioma Treatment Drugs @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook Report- https://www.delveinsight.com/report-store/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Diffuse Intrinsic Pontine Glioma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diffuse Intrinsic Pontine Glioma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diffuse Intrinsic Pontine Glioma clinical trial landscape.

Diffuse Intrinsic Pontine Glioma Overview
Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain's glial tissue - tissue made up of cells that help support and protect the brain's neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body's most vital functions such as breathing, blood pressure and heart rate.

Find out more about Diffuse Intrinsic Pontine Glioma Treatment Landscape @ Drugs for Diffuse Intrinsic Pontine Glioma Treatment- https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile
• MTX 110: Midatech
• Paxalisib: Kazia Therapeutics

Diffuse Intrinsic Pontine Glioma Pipeline Therapeutics Assessment
There are approx. 25+ Diffuse Intrinsic Pontine Glioma companies that are developing the Diffuse Intrinsic Pontine Glioma therapies. The Diffuse Intrinsic Pontine Glioma companies that have their Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage, i.e. phase I/II include, Midatech.

DelveInsight's Diffuse Intrinsic Pontine Glioma pipeline report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Diffuse Intrinsic Pontine Glioma Pipeline Therapies @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report
• Coverage- Global
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
• Diffuse Intrinsic Pontine Glioma Pipeline Therapies- BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.

Dive deep into rich insights for new drugs for Diffuse Intrinsic Pontine Glioma treatment, Visit @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Diffuse Intrinsic Pontine Glioma Overview
4. Diffuse Intrinsic Pontine Glioma Pipeline Therapeutics
5. Diffuse Intrinsic Pontine Glioma Therapeutic Assessment
6. Diffuse Intrinsic Pontine Glioma- DelveInsight's Analytical Perspective
7. Late Stage Diffuse Intrinsic Pontine Glioma Products (Phase III)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Diffuse Intrinsic Pontine Glioma Products (Phase I/II)
11. MTX 110: Midatech
12. Drug profiles in the detailed report…..
13. Early Stage Diffuse Intrinsic Pontine Glioma Products (Phase I)
14. Drug name : Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name : Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diffuse Intrinsic Pontine Glioma Companies
21. Diffuse Intrinsic Pontine Glioma Key Products
22. Diffuse Intrinsic Pontine Glioma Unmet Needs
23. Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers
24. Diffuse Intrinsic Pontine Glioma Future Perspectives and Conclusion
25. Diffuse Intrinsic Pontine Glioma Analyst Views
26. Diffuse Intrinsic Pontine Glioma Key Companies
27. Appendix

For further information on the Diffuse Intrinsic Pontine Glioma pipeline therapeutics, reach out to Diffuse Intrinsic Pontine Glioma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market

Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.